Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GH 
Guardant Health Inc (GH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: GH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $69.55
1 Year Target Price $69.55
| 15 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.03% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.16B USD | Price to earnings Ratio - | 1Y Target Price 69.55 |
Price to earnings Ratio - | 1Y Target Price 69.55 | ||
Volume (30-day avg) 24 | Beta 1.53 | 52 Weeks Range 20.14 - 68.23 | Updated Date 10/18/2025 |
52 Weeks Range 20.14 - 68.23 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.93% | Operating Margin (TTM) -45.75% |
Management Effectiveness
Return on Assets (TTM) -19.57% | Return on Equity (TTM) -4584.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8369429971 | Price to Sales(TTM) 9.85 |
Enterprise Value 8369429971 | Price to Sales(TTM) 9.85 | ||
Enterprise Value to Revenue 10.1 | Enterprise Value to EBITDA -5.4 | Shares Outstanding 124705857 | Shares Floating 119776234 |
Shares Outstanding 124705857 | Shares Floating 119776234 | ||
Percent Insiders 4.32 | Percent Institutions 99.05 |
Upturn AI SWOT
Guardant Health Inc
Company Overview
History and Background
Guardant Health was founded in 2012. It is a leading precision oncology company focused on conquering cancer through use of its blood tests, companion diagnostics, and data intelligence.
Core Business Areas
- Precision Oncology Testing: Develops and commercializes liquid biopsy tests (LDTs) for cancer detection and monitoring. These tests analyze circulating tumor DNA (ctDNA) in blood to identify genomic alterations relevant for treatment decisions and recurrence monitoring.
- Companion Diagnostics: Partners with pharmaceutical companies to develop companion diagnostics (CDx) tests. CDx tests are used to identify patients who are most likely to benefit from specific targeted therapies, facilitating personalized cancer treatment.
- Data Intelligence: Leverages its large database of genomic and clinical data to accelerate cancer research and drug development. Offers data solutions to pharmaceutical and academic researchers, providing insights into cancer biology and treatment outcomes.
Leadership and Structure
Helmy Eltoukhy (Co-Founder, CEO), AmirAli Talasaz (Co-Founder, President), Company has functional teams in R&D, commercial, and operations.
Top Products and Market Share
Key Offerings
- Guardant360: Comprehensive genomic profiling test for advanced-stage cancer patients. It identifies actionable genomic alterations to guide treatment decisions. Competitors include Foundation Medicine (FMI), Tempus. Market share is approximately 25-30% in advanced cancer comprehensive liquid biopsy testing (estimated). Revenue derived, not publicly specified, but this is their flagship product.
- Guardant Reveal: Minimal residual disease (MRD) test for early-stage cancer patients. It detects ctDNA to identify patients at high risk of recurrence after surgery or adjuvant therapy. Competitors include Natera (NTRA), Exact Sciences (EXAS) in MRD. Market share is still developing, but growing in the MRD space. Revenue not publicly specified.
- Guardant Shield: For average risk individuals to screen for colorectal cancer. Competitors include Exact Sciences (EXAS) and Freenome.
Market Dynamics
Industry Overview
The precision oncology market is rapidly growing, driven by increasing cancer incidence, advancements in genomic sequencing technologies, and the shift towards personalized medicine. Liquid biopsy is becoming increasingly important for treatment selection, monitoring, and early detection.
Positioning
Guardant Health is a leader in the liquid biopsy market, with a strong focus on comprehensive genomic profiling and companion diagnostics. It has a large and growing database of genomic and clinical data, providing a competitive advantage in data intelligence and research.
Total Addressable Market (TAM)
The estimated TAM for liquid biopsy is tens of billions of dollars, encompassing advanced cancer, early cancer, and screening applications. Guardant Health is well positioned to capture a significant share of this market with its broad product portfolio and established market presence.
Upturn SWOT Analysis
Strengths
- Leading position in liquid biopsy market
- Strong brand recognition
- Comprehensive genomic profiling capabilities
- Large and growing database of genomic and clinical data
- Strong relationships with pharmaceutical companies
Weaknesses
- High cost of testing
- Reimbursement challenges
- Competition from established players (FMI, EXAS, NTRA) and new entrants
- Regulatory uncertainty
Opportunities
- Expanding into new applications, such as early cancer detection and minimal residual disease monitoring
- Developing new companion diagnostics for targeted therapies
- Partnering with pharmaceutical companies to accelerate drug development
- Expanding into international markets
- Improving test accuracy and reducing costs
Threats
- Increased competition
- Price pressures
- Changes in reimbursement policies
- Technological advancements that could disrupt the market
- Unfavorable regulatory changes
Competitors and Market Share
Key Competitors
- FMI
- EXAS
- NTRA
- ILMN
Competitive Landscape
Guardant Health has a competitive advantage in comprehensive genomic profiling, while competitors like Exact Sciences have a stronger presence in early cancer detection. Illumina is a major player in sequencing technology, impacting the overall market.
Growth Trajectory and Initiatives
Historical Growth: Guardant Health has experienced strong revenue growth in recent years, driven by increasing adoption of its liquid biopsy tests. However, profitability remains a challenge.
Future Projections: Analysts project continued revenue growth for Guardant Health in the coming years, driven by expanding into new applications and markets. Profitability is expected to improve as the company achieves greater scale.
Recent Initiatives: Guardant Health has been investing in R&D to develop new and improved liquid biopsy tests. It has also been expanding its partnerships with pharmaceutical companies and expanding its presence internationally.
Summary
Guardant Health is a leading player in the growing liquid biopsy market, offering comprehensive genomic profiling and MRD detection. While facing competition and reimbursement challenges, the company possesses a strong market position and potential for growth driven by innovation, strategic partnerships, and expansion into new applications. Future success depends on successful product development, navigating regulatory hurdles, and achieving profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate. Financial data is subject to change. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Guardant Health Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Co-CEO & Chairman Dr. Helmy Eltoukhy Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1999 | Website https://guardanthealth.com |
Full time employees 1999 | Website https://guardanthealth.com | ||
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.